Skip to main content


Cannabis use disorder significantly raises the risk of medication noncompliance among inpatients with schizophrenia, according to a study published online in Schizophrenia Research.
A majority of inpatients with schizophrenia who were treated with electroconvulsive therapy (ECT) demonstrated clinical improvement, irrespective of whether they were capable of consenting before psychiatric treatment, a study found.
Janssen is seeking US Food and Drug Administration (FDA) approval for the first long-acting injectable (LAI) medication for schizophrenia that would be taken only twice a year.
Two advisory committees appointed by the US Food and Drug Administration (FDA) have voted in favor of ALKS 3831, a combination of olanzapine and the novel molecular entity samidorphan, Alkermes announced.
Patients initiated on long-acting injectables for the treatment of schizophrenia had fewer hospitalizations and emergency department visits, compared with patients treated with oral antipsychotics, according to a poster presented at Psych Congress…
What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications?
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top